Relapsed or Refractory Hematologic Malignancies
Conditions
Brief summary
This is a single-arm, open-label, multicenter, dose-escalation, dose-expansion and efficacy-expansion phase I clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary antitumor activity of QLS2309 injection in patients with CD70+ relapsed/refractory hematologic malignancies.
Interventions
DRUGQLS2309
initial dose - MTD; QW; intravenous infusion
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Subjects voluntarily participated and signed a written informed consent form * Age ≥ 18 years, male or female * ECOG performance status of 0-2 * Expected life-expectancy ≥ 3 months * CD70+ relapsed/refractory hematologic malignancies * Adequate organ function prior to QLS2309 administration * Female patients with fertility must agree to the use of effective contraceptive methods during the study period and within 35 days of discontinuation of the trial drug. * Male patients whose sexual partners are women of childbearing age must agree to use condoms during the study period and within 35 days of discontinuation of the trial drug during sexual intercourse.
Exclusion criteria
* Prior treatment with CD70-related antibodies, antibody-conjugated drugs (ADCs) or cell therapy products * Symptomatic central nervous system (CNS) involvement, leptomeningeal metastasis or spinal cord compression caused by metastasis * An active autoimmune diseases or known history of ≥ grade 3 irAE due to prior immunotherapy * Known history of other active malignant tumor within 3 years * Known history of chemotherapy, biological therapy, endocrine therapy, immunotherapy, monoclonal antibodies, etc. within 4 weeks * Known history of active hepatitis B/C infection, HIV infection, Treponema pallidum infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity(DLT) | 28 days | To evaluate the safety and tolerability of QLS2309 |
| Recommended Phase Ib Dose (RPIbD) | up to 2 years | The Safety Monitoring Committee (SMC) will select RP1bD based on the safety, tolerability, PK parameters, pharmacodynamics, preliminary effectiveness and other data of subjects in different dose groups |
Countries
China
Contacts
Primary ContactXiaojun Huang, MD
Outcome results
None listed